Company Profile

Soluble Therapeutics LLC (AKA: Soluble BioScience)
Profile last edited on: 7/5/19      CAGE: 59AL7      UEI: LES8FJS91BK5

Business Identifier: Formulation optimization for protein-based therapeutics
Year Founded
2008
First Award
2010
Latest Award
2015
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1500 First Avenue North
Birmingham, AL 35203
Location: Single
Congr. District: 07
County: Jefferson

Public Profile

In December 2016, Soluble Therapeutics, Inc (renamed Soluble BioScience) was acquired by CytoBioscience - a firm founded in Germany that in 2015 had moved its headquarters and manufacturing to San Antonio, TX. Soluble also relocated to San Antonio. Soluble had been founded to commercialize the HSC™ Technology licensed from the University of Alabama at Birmingham. The company’s services enhance the drug development process by rapidly optimizing protein solubility and stability. Soluble Therapeutics LLC has been working in formulation optimization for protein-based therapeutics. The company develops technology to keep high concentrations of proteins soluble and stable until they are ready to be used for research, therapeutics, vaccines, scientific reagents, and industrial enzymes. Dilyx Biotechnologies - Offers Protein Solubility analysis kits including reagent kits for protein folding, membrane protein solubilization, protein solubility and protein formulation. In 2014, Soluble had acquired the small firm Dilyx a life science products firm developing Kits providing protein solubility analysis & protein solubilization to avoid aggregat

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2015 1 NIH $153,004
Project Title: Development of a Novel Membrane Protein Solubilization/Stabilization Screen
2012 2 NIH $1,211,397
Project Title: Optimization of Protein Therapeutic Formulations

Key People / Management

  Joseph N Garner -- CEO

  Lawrence J Delucas